Quantum Genomics Information

The objective of Quantum Genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class: BAPAIs for BrainAminopeptidase A Inhibitors. We wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure. High blood pressure remains a major public health concern. Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain Aminopeptidase A. The mid-term strategic objective of the company is to sign partnership agreements with major pharmaceutical companies which will take over and bring the products from the BAPAI technology to the market.